RxDoctor Payments Data

Hector Sosa

Family · San Antonio, TXNPI 1336893403

Payments from drug & device makers

$6,709in general payments, 2019–2025

Across 309 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$987
  • AbbVie$711
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$430
  • GSK$418
  • Pfizer$380
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,709 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin12$37,740
OzempicSemaglutide21$21,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,071
FarxigaDapagliflozin Propanediol11$13,663
SymbicortBudesonide/Formoterol Fumarate12$2,908
Atomoxetine Hcl13$1,349
Fluticasone Propionate73$834
Omeprazole37$649
Levothyroxine Sodium70$639
Rosuvastatin Calcium58$604
Cefdinir27$564
Gabapentin50$515
Atorvastatin Calcium71$473
Naproxen56$402
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$37,74012 claims
Novo NordiskOzempic$1,505$21,78621 claims
GSKTrelegy Ellipta$418$19,07114 claims
AstraZenecaFarxiga, Symbicort$987$16,57023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →